Public Health England calls for action against growing UK opioid crisis threat
September 10, 2019Manufacturing and Production opioid addiction, phe
Public Health England (PHE) have stated that there are far too many people on prescribed drugs that can cause dependence …
MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland
September 10, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma
MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …
Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease
September 10, 2019Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, FDA, US, lungs, ofev, pharma, rare disease
Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of …
SMC gives nod for access to new HIV treatment Dovato
September 10, 2019Manufacturing and Production HIV, SMC
The Scottish Medicines Consortium (SMC) has approved Dovato (dolutegravir/lamivudine) for use on the NHS, allowing treatment of individuals with a …
Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine
September 10, 2019Manufacturing and Production, Sales and Marketing Alzheimer's, Alzheimers, Axon
Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine AADvac1 to slow the progression …
Novo Nordisk set to launch price cut for insulin drug NovoLog after harsh criticism over prices in the US
September 9, 2019Sales and Marketing Novo Nordisk, NovoLog, insulin
Danish drug maker Novo Nordisk has said it will offer a generic version of NovoLog (insulin aspart) at a price …
Lilly’s LOXO-292 shrinks tumours in lung cancer trial
September 9, 2019Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma
Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …
Age affects efficacy of immunotherapy treatments in breast cancer patients
September 9, 2019Research and Development, Sales and Marketing Cancer, breast cancer, pharma
Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …
Trump’s FDA: Is the US regulator being steered by the President?
September 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Trump, US, drug safety, pharma
FDA activity has fallen under Donald Trump, with the number of warning letters issued by the regulator dropping by a …
4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine
September 9, 2019Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma
Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …
AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer
September 9, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …
Top Ten most popular articles on Pharmafile.com this week
September 6, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Mylan, brexit
It’s Friday, meaning the weekend is within reach and it’s time for a rundown of the most popular articles on …
Roche celebrates European approval of Tecentriq combo in first-line lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq
Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …
Novartis’ Lucentis secures European approval for infants with rare eye disease
September 6, 2019Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma
Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …
Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma
Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …
View of pharma industry sinks to new low in US, poll reveals
September 6, 2019Medical Communications US, pharma
The public have always been reticent with their trust in the pharmaceutical industry, but that trust has hit an all-time …
Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal
September 5, 2019Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma
Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …
Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis
September 5, 2019Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis
Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …
BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme
September 5, 2019Research and Development BMS, glioblastoma multiforme, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the …
Cancer drugs have surged since the 80s to account for 1 in 4 FDA approvals, report reveals
September 5, 2019Research and Development, Sales and Marketing Cancer, FDA, US, pharma
The number of cancer drug approvals in the US has surged over the last decade to account for over one …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
